ArticleOncology and therapy2024

Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy.

Luca Scafuri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.